The decline in operating income was primarily a result of ourinvestments in R&D, which increased $470,000 from the first quarter of 2008.Expenses related to our IT initiative also affected 2009 operating income. Revenue in our brachytherapy segment declined 12% compared to the 2008 period.Operating income in the brachytherapy segment was $1.1 million compared to $1.7million in the first quarter 2008. This decline in operating income reflects thedecrease in sales. Expenses related to our IT initiative also affected ourbrachytherapy results in 2009. “Our surgical products business delivered excellent results in the first quarterwith 12% year over year pro forma revenue growth,” stated M Christine Jacobs,Chairman and CEO. “Although we continue to see softness in brachytherapyprocedures, a trend that is likely to continue, our brachytherapy businessremained profitable and continues to be an important contributor to ourstrategy.” Ms. Jacobs continued, “We believe that recording our highest quarterly revenueever, especially in the current economic environment, is a good start for 2009.We have maintained profitability while investing in our important strategicinitiatives.

Our R&D initiative is well underway and our information technologyprogram was initiated in the first quarter. The inherent variability in oursurgical products business, along with continued difficulties in themacroeconomic environment, will continue to make it extremely difficult topredict 2009 and 2010. Nevertheless, we experienced positive first quarterresults, look forward to pipeline improvements and continued growth from ourdiversification efforts. We expect to continue to invest and execute plans forour long-term sustainable growth.” Tables I and II to this press release contain condensed consolidated statementsof earnings and balance sheets. Pro forma revenue by segment is summarized inTable III, and operating income by segment is summarized in Table IV. Table Vincludes a reconciliation of GAAP reported net earnings to earnings beforeinterest, taxes, depreciation and amortization (EBITDA) Theragenics will host a conference call today at 11:00 a.m Eastern Time.

Toaccess the call, dial 800-538-9844 or 706-634-7274 and provide the conference ID95649664. This call is also being broadcast live over the Internet, and arecording will be available for one month on our website. To access the webcast,log on to and select Investor Relations followed byselecting “Company Presentations.” You also can access a phone replay of thecall until Midnight, May 14, 2009 by dialing 800-642-1687 or 706-645-9291 andproviding the conference ID code: 95649664. Theragenics Corporation (NYSE: TGX) operates two business segments: its surgicalproducts business and its brachytherapy seed business. Our surgical productsbusiness (, , )manufactures and distributes wound closure, vascular access, and specialtyneedle products. Wound closure products include sutures, needles and othersurgical products. Vascular access includes introducers, guidewires and relatedproducts.

Specialty needles include coaxial, biopsy, spinal and disposableveress needles, access trocars, and other needle-based products. Our surgicalproducts segment serves a number of markets and applications, including, amongother areas, interventional cardiology, interventional radiology, vascularsurgery, orthopedics, plastic surgery, dental surgery, urology, veterinarymedicine, pain management, endoscopy, and spinal surgery. Our brachytherapybusiness manufactures and markets its premier product, the palladium-103TheraSeed® device () and I-Seed, an iodine-125 based device,which are used primarily in the minimally invasive treatment of localizedprostate cancer. EBITDA is used to establish financial and operational goals, to monitorour actual performance in relation to our business plan and operating budgets,and as part of several components we consider in determining incentivecompensation.

We recognize that the use of non-GAAP measures has limitations,including the fact that they may not be directly comparable with similarnon-GAAP financial measures used by other companies. All non-GAAP financialmeasures are intended to supplement the applicable GAAP disclosures and shouldnot be considered in isolation from, or as substitute for, financial informationprepared in accordance with GAAP. For a reconciliation of non-GAAP measures fromGAAP reported amounts, please see the supplemental information included withthis press release.This press release contains forward looking statements within the meaning of thePrivate Securities Litigation Reform Act of 1995, the accuracy of which isnecessarily subject to risks and uncertainties, including, without limitation,statements regarding future growth, opportunities and investments, andanticipated positive results in general. This unaudited pro forma information is not intended to represent or be indicative of the Company`s consolidated results of operations or financial condition that would have been reported had the acquisition been completed as of January 1, 2008, and should not be taken asindicative of the Company`s future consolidated results of operations or financial condition.Quarter Ended Apr 5, 2009 Quarter Ended Mar 30, 2008 SurgicalBrachy-Interseg Consolidated Surgical Brachy-Interseg Consolidated Productstherapy seed elim.Products therapyelim. seedRevenue, $13,149 $6,987$ (59 ) $20,077$7,320 $7,966$ (51 ) $15,235U.S. GAAP$607 $ 1,636 Income tax expense477 931 Interest income (11)(459 )Interest expense129 146 Other non-operating income/expense2 (4 )Operating income1,204 2,250 Depreciation and amortization 1,717 1,180 Share based compensation amortization 148 218 EBITDA (a) $3,069 $ 3,648 (a) Represents a non GAAP financial measure.See page 3 of this press release for information on non-GAAP financialmeasures.The Company has historically referred to earnings before interest, taxes, depreciation, amortization andshare based compensation as “EBITDA.” TheragenicsFrank Tarallo, CFO & TreasurerorLisa Rassel, Manager of Investor RelationsPhone: 800-998-8479 – 770-271-0233Website: Business Wire 2009.